Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
University of Miami - Comprehensive Hemophilia Center
mi
from
Miami, FL
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
University of Miami - Comprehensive Hemophilia Center
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
St. Luke's Boise Medical Center
mi
from
Boise, ID
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
St. Luke's Boise Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
Rush University Medical Center
mi
from
Chicago, IL
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
Michigan State University Center for Bleeding Disorders & Clotting Disorders
mi
from
East Lansing, MI
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
Michigan State University Center for Bleeding Disorders & Clotting Disorders
mi
from
East Lansing, MI
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
Children's Mercy Hospital, Kansas City Regional Hemophilia Center
mi
from
Kansas City, MO
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
Children's Mercy Hospital, Kansas City Regional Hemophilia Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
Long Island Jewish Medical Center - Hemophilia Treatment Center
mi
from
New Hyde Park, NY
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
Long Island Jewish Medical Center - Hemophilia Treatment Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated:  7/2/2014
Oregon Health and Science University
mi
from
Portland, OR
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A
Status: Enrolling
Updated: 7/2/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated:  7/30/2014
Intermountain Medical Center
mi
from
Murray, UT
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated: 7/30/2014
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated:  7/30/2014
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated: 7/30/2014
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated:  7/30/2014
University Of Utah Hospital
mi
from
Salt Lake City, UT
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates
Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.
Status: Enrolling
Updated: 7/30/2014
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
Pathobiology of Kidney Disease: Role of Iron
Status: Enrolling
Updated:  9/26/2014
VA Medical Center
mi
from
Indianapolis, IN
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
Pathobiology of Kidney Disease: Role of Iron
Status: Enrolling
Updated: 9/26/2014
VA Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
Status: Enrolling
Updated:  12/4/2014
University of Utah
mi
from
Salt Lake City, UT
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
Status: Enrolling
Updated: 12/4/2014
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated:  12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
mi
from
St. Louis, MO
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated: 12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy
Status: Enrolling
Updated:  12/17/2014
Clinical Research Facility
mi
from
Baltimore, MD
A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo
A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy
Status: Enrolling
Updated: 12/17/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Red Blood Cell (RBC) Survival Following Transfusion in Infants
Red Blood Cell Survival Following Transfusion in Infants
Status: Enrolling
Updated:  12/23/2014
University of Iowa
mi
from
Iowa City, IA
Red Blood Cell (RBC) Survival Following Transfusion in Infants
Red Blood Cell Survival Following Transfusion in Infants
Status: Enrolling
Updated: 12/23/2014
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Red Blood Cell (RBC) Survival Following Transfusion in Infants
Red Blood Cell Survival Following Transfusion in Infants
Status: Enrolling
Updated:  12/23/2014
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Red Blood Cell (RBC) Survival Following Transfusion in Infants
Red Blood Cell Survival Following Transfusion in Infants
Status: Enrolling
Updated: 12/23/2014
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease
Status: Enrolling
Updated:  2/2/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease
Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease
Status: Enrolling
Updated: 2/2/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Medication Adherence in Youth With Sickle Cell Disease (SCD)
Use of WISE Device Technology to Measure Medication Adherence in Youth With Sickle Cell Disease (SCD): A Pilot Study
Status: Enrolling
Updated:  2/11/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Medication Adherence in Youth With Sickle Cell Disease (SCD)
Use of WISE Device Technology to Measure Medication Adherence in Youth With Sickle Cell Disease (SCD): A Pilot Study
Status: Enrolling
Updated: 2/11/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Mayo Clinic Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic
mi
from
Jacksonville, FL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Wichita
mi
from
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Duluth
mi
from
Duluth, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Merit Care Hospital
mi
from
Fargo, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Altru Cancer Center
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Toledo Community Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Oklahoma
mi
from
Tulsa, OK
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Oklahoma
mi
from
Tulsa, OK
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated:  7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer
Status: Enrolling
Updated: 7/7/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Boston, MA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Cleveland, OH
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Orange, CA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Sacramento, CA
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Tampa, FL
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
East Lansing, MI
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
East Lansing, MI
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
Clinical Research Facility
mi
from
Kansas City, MO
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated:  7/14/2015
mi
from
Bahia Blanca,
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy
Status: Enrolling
Updated: 7/14/2015
mi
from
Bahia Blanca,
Click here to add this to my saved trials
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Status: Enrolling
Updated:  7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Status: Enrolling
Updated: 7/14/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Long Term Effects of Erythrocyte Lysis
Long Term Effects of Erythrocyte Lysis
Status: Enrolling
Updated:  7/20/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Long Term Effects of Erythrocyte Lysis
Long Term Effects of Erythrocyte Lysis
Status: Enrolling
Updated: 7/20/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated:  7/21/2015
DaVita Arvada Dialysis Center
mi
from
Arvada, CO
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated: 7/21/2015
DaVita Arvada Dialysis Center
mi
from
Arvada, CO
Click here to add this to my saved trials
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated:  7/21/2015
DaVita Minneapolis Dialysis Unit
mi
from
Minneapolis, MN
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Status: Enrolling
Updated: 7/21/2015
DaVita Minneapolis Dialysis Unit
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Dayton, OH
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated:  8/12/2015
Clinical Research Facility
mi
from
Houston, TX
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)
Status: Enrolling
Updated: 8/12/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials